Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients.
Medrano C, Oberic L, Puisset F, Recher C, Larrieu-Ciron D, Ysebaert L, Protin C, Picard M, Perriat S, Chatelut E, Bertoli S, Huguet F, Tavitian S, Faguer S. Medrano C, et al. Among authors: protin c. Leuk Lymphoma. 2021 Apr;62(4):846-853. doi: 10.1080/10428194.2020.1846733. Epub 2020 Nov 12. Leuk Lymphoma. 2021. PMID: 33179543
Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
Lapierre L, Pericart S, Protin C, Borel C, Ysebaert L, Laurent C, Oberic L. Lapierre L, et al. Among authors: protin c. Leuk Lymphoma. 2021 Dec;62(12):3063-3065. doi: 10.1080/10428194.2021.1950711. Epub 2021 Jul 13. Leuk Lymphoma. 2021. PMID: 34254883 No abstract available.
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Sibaud V, et al. Among authors: protin c. Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x. Am J Clin Dermatol. 2020. PMID: 32613545 Review.
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A. Godet S, et al. Among authors: protin c. Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. Am J Hematol. 2018. PMID: 29164674 Free article. No abstract available.
Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
Ribes D, Hachem HEL, Oberic L, Vergez F, Delas A, Belliere J, Protin C, Kamar N, Ferrandiz I, Tavitian S, Laurent C, Huart A, Chauveau D, Ysebaert L, Faguer S. Ribes D, et al. Among authors: protin c. Am J Hematol. 2018 Mar;93(3):356-362. doi: 10.1002/ajh.24984. Epub 2017 Dec 6. Am J Hematol. 2018. PMID: 29168251 Free article.
Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.
Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, Dupont M, Dreyfus B, Ferrant E, Herbaux C, Laribi K, Le Calloch R, Malphettes M, Paul F, Souchet L, Truchan-Graczyk M, Delavigne K, Dartigeas C, Ysebaert L; French Innovative Leukemia Organization (FILO) CLL group. Ghez D, et al. Among authors: protin c. Blood. 2018 Apr 26;131(17):1955-1959. doi: 10.1182/blood-2017-11-818286. Epub 2018 Feb 1. Blood. 2018. PMID: 29437588 Free article. Clinical Trial.
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Guidez S, Labreuche J, Drumez E, Ysebaert L, Bakala J, Delette C, Hivert B, Protin C, Declercq H, Verlay M, Marolleau JP, Duhamel A, Morel P; French Innovative Leukemia Organization (FILO) CLL group. Guidez S, et al. Among authors: protin c. Blood Adv. 2018 Nov 27;2(22):3102-3111. doi: 10.1182/bloodadvances.2018021287. Blood Adv. 2018. PMID: 30455359 Free PMC article.
24 results